AlphAIalphai — Financial news for AI agents
prnewswire.comAUG 54 min read$SOLV

Solventum Reports Second Quarter 2026 Financial Results

Solventum (NYSE: SOLV) reported Q2 2026 sales of $2.2 billion, up 2.2% reported and 9.5% organic. GAAP diluted EPS was $0.53, adjusted $2.55. Operating cash flow was $227 million and free cash flow $144 million. The company said it intends to separate its Health Information Systems segment and raised full-year 2026 guidance for organic sales growth, adjusted EPS and free cash flow.

Original reporting
prnewswire.com
Published Aug 5, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Solventum Reports Second Quarter 2026 Financial Results — source image
Source · prnewswire.com
Decision brief

The 30-second read

$SOLVBullishHigh
01

Why it matters

The combination of Q2 execution, higher full-year guidance, and an announced intent to separate a business segment provides both near-term earnings/cash-flow signals and longer-term portfolio re-positioning.

02

Market read

Traders can update models immediately using the raised 2026 organic sales, adjusted EPS, and free cash flow ranges, while also repricing separation-related optionality and cost trajectory.

03

What to watch

Investors will likely focus on the separation process details (timing, costs, tax impacts) and whether organic growth sustains after advance orders and SKU exit effects fade.

Relevance 9/10Novelty 9/10Timing: after-hours today, Aug. 5, with guidance update and same-day earnings call

Background

Solventum is in a transformation strategy toward a more focused MedTech profile and is reviewing/separating its Health Information Systems segment.

Company-level read

Ticker impact

$SOLVBullishHigh confidence
Context

Solventum reported Q2 results and raised full-year 2026 guidance for organic sales growth, adjusted EPS, and free cash flow.

Expected impact

Near-term bias upward on guidance and separation optionality; follow-through depends on investor reaction to the separation timeline and any legal cost normalization.

Evidence & confidence

The article discloses specific Q2 performance metrics and explicit upward guidance ranges, plus a concrete corporate action intent to separate a business segment.

Market effects

Sector

MedTech peers may see read-across on how separation and ERP timing benefits can affect reported margins and cash flow.

Regional

Limited direct regional impact; primarily company-specific within US healthcare/MedTech.

Global

IEEPA tariff refund and ERP timing suggest cross-border policy and systems execution can swing margins, relevant for multinational healthcare suppliers.

Counterpoint

What could challenge this read

Adjusted strength may be partly driven by one-time items (tariff refund, ERP timing) and elevated legal/separation costs could pressure future quarters.

Key entities

  • company
    Solventum

    Reports Q2 2026 results, updates full-year 2026 guidance, and announces intent to separate its Health Information Systems segment.

  • person
    Bryan Hanson

    CEO quoted on execution and transformation progress.

Read at source← All news

Related articles

AUG 6
$SOLVMedAI 8/10

Solventum to hive off healthcare software business, raises profit forecast

Solventum said it will separate its health information systems software business, leaving MedSurg and Dental Solutions, as part of its turnaround. The unit accounted for 16.3% of 2025 sales. Solventum raised 2026 organic sales growth to 2.5% to 3% and adjusted profit per share to $7.10 to $7.20. Q2 adjusted EPS was $2.55 on revenue of $2.21B, beating LSEG estimates.

wixx.com4 min
AUG 5
$SOLVMedAI 8/10

Solventum (NYSE:SOLV) Posts Better

Solventum (NYSE:SOLV) reported Q2 CY2026 results with revenue up 2.2% year on year to $2.21 billion, beating market expectations. Non-GAAP EPS was $2.55, 33.8% above analysts’ consensus. The article also cites trailing 12-month sales of $8.31 billion, flat over two years, and Q2 free cash flow of $144 million. Shares rose 3.7% to $90.75.

financialcontent.com5 min
AUG 5
$SOLVHigh

Solventum Corp (SOLV): Results of Operations and Financial Condition

Solventum Corp (SOLV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026-8kerexx991.htm EX-99.1 Document Exhibit 99.1 Solventum Reports Second Quarter 2026 Financial Results • R eported sales increased 2.2%; organic sales increased 9.5% • Announces intent to separate its Health Information Systems business segment • Increases full-yea

SEC EDGAR 8-K6 min
MAY 26
$SOLVMedAI 8/10

Weekly Research Analysts’ Ratings Changes for Solventum (SOLV)

Solventum (NYSE: SOLV) saw multiple analyst rating and target changes. Wedbush initiated coverage with an “outperform” rating and $94 target (5/15/26). UBS downgraded to “neutral” with $50 target (5/14/26) and previously cut its target to $78 (5/6/26). Other firms adjusted targets and ratings on 5/6/26, including Stifel ($90, buy), KeyCorp ($93, overweight), Wells Fargo ($70, equal weight), and BTIG ($89, buy). Director Amy Mcbride Wendell bought 1,475 shares at $68.03 (3/10/26).

tickerreport.com1 min
AUG 7
$AIXCMed

AIxCrypto Holdings, Inc. (AIXC): Results of Operations and Financial Condition

AIxCrypto Holdings, Inc. (AIXC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 AIxCrypto Holdings Reports Second Quarter 2026 Results RoboShare Introduced Successfully and Designated Top Operating Priority for the Second Half of 2026; Operating Expenses Decline 32% Sequentially ● Introduced RoboShare, an on-demand r

SEC EDGAR 8-K6 min
AUG 7
$AMDMed

AMD's Beat-and-Raise Q2 Earnings Shows Just How High the AI Bar Is

AMD reported Q2 results that beat on revenue and earnings and raised guidance, while projecting capital expenditures to more than double to $808 million from $389 million to expand capacity for EPYC processors and Helios rack-scale AI systems. The higher spending may pressure margins and free cash flow near term, contributing to a negative stock reaction, but management expects strong data center growth.

yahoo.com5 min